Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade F 11.55 -1.45% -0.17
NCNA closed down 1.45 percent on Tuesday, February 19, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical NCNA trend table...

Date Alert Name Type % Chg
Feb 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 19 Narrow Range Bar Range Contraction 0.00%
Feb 19 NR7 Range Contraction 0.00%
Feb 19 NR7-2 Range Contraction 0.00%
Feb 19 Inside Day Range Contraction 0.00%
Feb 19 Wide Bands Range Expansion 0.00%
Feb 15 MACD Bullish Signal Line Cross Bullish -1.45%
Feb 15 Narrow Range Bar Range Contraction -1.45%
Feb 15 NR7 Range Contraction -1.45%
Feb 15 Inside Day Range Contraction -1.45%

Older signals for NCNA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.0
52 Week Low 10.37
Average Volume 73,073
200-Day Moving Average 20.3954
50-Day Moving Average 14.3292
20-Day Moving Average 12.121
10-Day Moving Average 11.458
Average True Range 1.2794
ADX 14.13
+DI 14.5751
-DI 20.7976
Chandelier Exit (Long, 3 ATRs ) 13.5218
Chandelier Exit (Short, 3 ATRs ) 14.2082
Upper Bollinger Band 14.0865
Lower Bollinger Band 10.1555
Percent B (%b) 0.35
BandWidth 32.431318
MACD Line -0.9346
MACD Signal Line -1.0121
MACD Histogram 0.0775
Fundamentals Value
Market Cap 367.42 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -28.88
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.95
Resistance 3 (R3) 11.99 11.90 11.88
Resistance 2 (R2) 11.90 11.80 11.88 11.86
Resistance 1 (R1) 11.73 11.74 11.68 11.68 11.84
Pivot Point 11.64 11.64 11.62 11.62 11.64
Support 1 (S1) 11.46 11.54 11.42 11.42 11.26
Support 2 (S2) 11.37 11.47 11.35 11.24
Support 3 (S3) 11.20 11.37 11.22
Support 4 (S4) 11.15